Evotec partners up on metabolic R&D; Debiopharm taps Yale for computer-aided development;

> Evotec has signed a deal with Germany's Eternygen to team up on small-molecule drugs for metabolic diseases. More

> Debiopharm is partnering with Yale University to use the school's computer-aided drug discovery methods. News

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.